Author:
Kuo Ming-Che,Chu Yung-Tsai,Su Yu-An,Chen Meng-Ling,Wu Ruey-Meei
Abstract
AbstractPolymorphisms in the PSAP gene, which encodes prosaposin and is involved in the lysosomal function, yielded conflicting results regarding the association with Parkinson’s disease (PD). Therefore, this study aims to investigate the role of PSAP in familial PD (FPD), early onset PD (EOPD) with age at onset before 50 years old, and sporadic PD (SPD) among Taiwanese population, and summarize relevant studies via meta-analysis. By sequencing exon 1 to 14 in 183 FPD and 219 EOPD, two novel exonic variants were found in EOPD, including p.A146E (c.437C > A) on exon 5 and p.Y248C (c.743A > G) on exon 7. Furthermore, four previously reported intronic variants (rs142614739/rs74733861), rs749823, rs4747203 and rs885828) in intron 11 and 12 were analyzed in 485 SPD and 712 in-hospital controls, in addition to the aforementioned FPD and EOPD groups. The adjusted odd ratios (ORs) by age and sex, only rs142614739 was significantly associated with higher risk of EOPD (OR = 1.85, 95% CI = 1.33–2.58). The risk effect was further confirmed by the meta-analysis of the association between rs142614739 and the risk of PD in both common effect (OR = 1.29, 95% CI = 1.11–1.50) and random effect (OR = 1.29, 95% CI = 1.11–1.50). Our findings suggest that the PSAP rs142614739 variant is associated with the risk of EOPD. Further functional studies are warranted to elucidate the biochemical mechanisms.
Funder
Ministry of Science and Technology, Taiwan
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Bloem, B. R., Okun, M. S. & Klein, C. Parkinson’s disease. Lancet 397, 2284–2303. https://doi.org/10.1016/S0140-6736(21)00218-X (2021).
2. Chu, Y. T., Tai, C. H., Lin, C. H. & Wu, R. M. Updates on the genetics of Parkinson’s disease: Clinical implications and future treatment. Acta Neurol. Taiwan 30(3), 83–93 (2021).
3. Klein, A. D. & Mazzulli, J. R. Is Parkinson’s disease a lysosomal disorder?. Brain 141, 2255–2262. https://doi.org/10.1093/brain/awy147 (2018).
4. Sardi, S. P. et al. Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models. Proc. Natl. Acad. Sci. USA 114, 2699–2704. https://doi.org/10.1073/pnas.1616152114 (2017).
5. Lee, J. S. et al. Arylsulfatase A, a genetic modifier of Parkinson’s disease, is an alpha-synuclein chaperone. Brain 142, 2845–2859. https://doi.org/10.1093/brain/awz205 (2019).